Akebia Ther Company Insiders
AKBA Stock | USD 1.26 0.06 4.55% |
Akebia Ther's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Akebia Ther suggests that vertually all insiders are panicking. Akebia Ther employs about 167 people. The company is managed by 47 executives with a total tenure of roughly 259 years, averaging almost 5.0 years of service per executive, having 3.55 employees per reported executive.
John Butler CEO CEO and President and Director |
Muneer Satter Chairman Independent Chairman of the Board |
Akebia Ther's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-02-29 | Nicole R Hadas | Disposed 5974 @ 1.58 | View | ||
2024-02-27 | Nicole R Hadas | Disposed 7411 @ 1.52 | View | ||
2024-02-01 | Steven Keith Burke | Disposed 24311 @ 1.68 | View | ||
2023-05-25 | Nicole R Hadas | Disposed 63186 @ 1.22 | View | ||
2023-05-16 | Steven Keith Burke | Disposed 63567 @ 1.07 | View |
Monitoring Akebia Ther's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Akebia |
Akebia Ther Management Team Effectiveness
The company has return on total asset (ROA) of (0.0931) % which means that it has lost $0.0931 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5345) %, meaning that it created substantial loss on money invested by shareholders. Akebia Ther's management efficiency ratios could be used to measure how well Akebia Ther manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.78, whereas Return On Tangible Assets are forecasted to decline to (0.37). At present, Akebia Ther's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 182 M, whereas Other Current Assets are forecasted to decline to about 12.6 M.As of May 1, 2024, Common Stock Shares Outstanding is expected to decline to about 97.4 M. In addition to that, Net Loss is expected to decline to about (87.5 M)
Akebia Ther Workforce Comparison
Akebia Ther is rated third in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 850. Akebia Ther retains roughly 167 in number of employees claiming about 20% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.05 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.05. Akebia Ther Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akebia Ther insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akebia Ther's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Akebia Ther insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nicole Hadas over a month ago Acquisition by Nicole Hadas of 200000 shares of Akebia Ther subject to Rule 16b-3 | ||
Steven Burke over two months ago Disposition of 7169 shares by Steven Burke of Akebia Ther at 1.58 subject to Rule 16b-3 | ||
John Butler over two months ago Disposition of 37733 shares by John Butler of Akebia Ther at 1.52 subject to Rule 16b-3 | ||
David Spellman over six months ago Sale by David Spellman of 63567 shares of Akebia Ther | ||
David Spellman over a year ago Sale by David Spellman of 75 shares of Akebia Ther |
Akebia Ther Notable Stakeholders
An Akebia Ther stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Akebia Ther often face trade-offs trying to please all of them. Akebia Ther's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Akebia Ther's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John MBA | President, CEO | Profile | |
John Butler | CEO and President and Director | Profile | |
Muneer Satter | Independent Chairman of the Board | Profile | |
John Rice | Chairman of the Board | Profile | |
Adrian Adams | Independent Chairman of the Board | Profile | |
Steven Burke | Senior Vice President Chief Medical Officer | Profile | |
Dell Faulkingham | Senior Vice President Chief Commercial Officer | Profile | |
Ramin FarzanehFar | Vice President - Medical Research | Profile | |
Rita Jain | Senior Vice President Chief Medical Officer | Profile | |
Brad Maroni | Senior Vice President Chief Medical Officer | Profile | |
Theresa McNeely | Senior Vice President Corporate Communications & Investor Relations | Profile | |
Michel Dahan | Senior Vice President and Chief Business Officer | Profile | |
Karen Tubridy | Senior Vice President Chief Development Officer | Profile | |
Mark Rosch | Vice President - Regulatory Affairs | Profile | |
Bradley Maroni | Senior Vice President Chief Medical Officer | Profile | |
Ed Joyce | Vice President - Investor Relations and Corporate Communications | Profile | |
Jason Amello | CFO, Sr. VP and Treasurer | Profile | |
CGMA CPA | CFO VP | Profile | |
Teresa Compton | Chief Scientific Officer and Sr. VP | Profile | |
Nicole Hadas | Sr. VP, General Counsel and Secretary | Profile | |
Ronald Renaud | Director | Profile | |
Michael Heffernan | Director | Profile | |
Michael Rogers | Director | Profile | |
Scott Canute | Director | Profile | |
Jodie Morrison | Director | Profile | |
Duane Nash | Independent Director | Profile | |
Michael Wyzga | Independent Director | Profile | |
Steven Gilman | Director | Profile | |
Michael Clayman | Director | Profile | |
Cynthia Smith | Director | Profile | |
Maxine Gowen | Director | Profile | |
Mark Enyedy | Director | Profile | |
Tamara Dillon | VP of HR | Profile | |
Nicole JD | Chief VP | Profile | |
Kristie Bolieau | VP Controller | Profile | |
Carolyn Rucci | Senior Counsel | Profile | |
Kimberly Garko | Senior Officer | Profile | |
Steven MD | Senior Officer | Profile | |
Mercedes Carrasco | Director Communications | Profile | |
David Spellman | CFO VP | Profile | |
Tracey Vetterick | Vice Administration | Profile | |
Thierry Bilbault | VP Devel | Profile | |
Douglas MBA | Vice Strategy | Profile | |
Nicholas Grund | Senior Officer | Profile | |
Meredith Bowman | Senior Officer | Profile | |
Richard Malabre | Chief Officer | Profile | |
Violetta Cotreau | Chief VP | Profile |
About Akebia Ther Management Performance
The success or failure of an entity such as Akebia Ther often depends on how effective the management is. Akebia Ther management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Akebia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Akebia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.35) | (0.37) | |
Return On Capital Employed | (0.32) | (0.34) | |
Return On Assets | (0.21) | (0.23) | |
Return On Equity | 1.70 | 1.78 |
The data published in Akebia Ther's official financial statements usually reflect Akebia Ther's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Akebia Ther. For example, before you start analyzing numbers published by Akebia accountants, it's critical to develop an understanding of what Akebia Ther's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Akebia Ther's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akebia Ther's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Akebia Ther's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Akebia Ther. Please utilize our Beneish M Score to check the likelihood of Akebia Ther's management manipulating its earnings.
Akebia Ther Workforce Analysis
Traditionally, organizations such as Akebia Ther use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Akebia Ther within its industry.Akebia Ther Manpower Efficiency
Return on Akebia Ther Manpower
Revenue Per Employee | 1.2M | |
Revenue Per Executive | 4.1M | |
Net Loss Per Employee | 310.9K | |
Net Loss Per Executive | 1.1M | |
Working Capital Per Employee | 109.5K | |
Working Capital Per Executive | 388.9K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akebia Ther. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.Note that the Akebia Ther information on this page should be used as a complementary analysis to other Akebia Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Akebia Stock analysis
When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Akebia Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akebia Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.28) | Revenue Per Share 1.038 | Quarterly Revenue Growth 0.007 | Return On Assets (0.09) | Return On Equity (5.53) |
The market value of Akebia Ther is measured differently than its book value, which is the value of Akebia that is recorded on the company's balance sheet. Investors also form their own opinion of Akebia Ther's value that differs from its market value or its book value, called intrinsic value, which is Akebia Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akebia Ther's market value can be influenced by many factors that don't directly affect Akebia Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akebia Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine if Akebia Ther is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.